However, in a recent clinical study on advanced non-small cell lung carcinoma, one patient developed CRS after receiving three cycles of CAR–NK92 cells [clinicaltrials.gov ID: NCT03656705], with a reported 10-fold increase in IFN-γ and TNF-α levels. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.